Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
AngioChem Inc
Apteeus SAS
AVROBIO Inc
Bioasis Technologies Inc
Biorchestra Co Ltd
Capsida Biotherapeutics Inc
Deli Therapeutics Inc
Esteve Pharmaceuticals SA
GC Biopharma Corp
Generium
Homology Medicines Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
ReqMed Co Ltd
Sigilon Therapeutics Inc
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
BMRD-001 - Drug Profile
Product Description
Mechanism Of Action
CAP-001 - Drug Profile
Product Description
Mechanism Of Action
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate Idurote 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
GNR-055 - Drug Profile
Product Description
Mechanism Of Action
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
ISP-002 - Drug Profile
Product Description
Mechanism Of Action
Mucopolysaccharidosis Type II - Drug Profile
Product Description
Mechanism Of Action
pabifusp alfa - Drug Profile
Product Description
Mechanism Of Action
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
Recombint Idurote 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
SIG-018 - Drug Profile
Product Description
Mechanism Of Action
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
Featured News & Press Releases
Sep 15, 2022: UK MHRA approves Avrobio’s Phase I/II Hunter syndrome therapy trial
Jul 14, 2022: Avrobio receives orphan drug desigtion for Hunter syndrome gene therapy
Feb 15, 2022: JCR announces first patient dosed in phase 3 global clinical trial of JR-141 for treatment of MPS II (Hunter Syndrome)
Feb 10, 2022: Homology medicines announces presentations on HMI-203 investigatiol gene therapy for Hunter syndrome and broad applicability of AAVHSC platform for lysosomal storage disorders at the 18th Annual WORLDSymposium meeting
Feb 09, 2022: JCR pharmaceuticals to present posters on JR-141 at the 18th annual WORLDSymposium 2022
Feb 03, 2022: JCR Pharmaceuticals receives the WORLDSymposium new treatment award for IZCARGO (Pabifusp Alfa)
Nov 29, 2021: Immusoft receives $4M in funding from the California Institute for Regenerative Medicine (CIRM)
Nov 08, 2021: AVROBIO to present preclinical data on AVRRD-05 at the 14th ICIEM Conference
Nov 03, 2021: AVROBIO receives Rare Pediatric Disease Desigtion from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Nov 02, 2021: GC Green Cross desigted as a European orphan drug for the treatment of severe Hunter syndrome
Oct 20, 2021: Homology Medicines announces presentation of data supporting clinical programs in MPS II and PKU, including nonclinical and patient-focused research, at American Society of Human Genetics Meeting
Oct 18, 2021: Homology medicines initiates clinical trial for HMI-203, a one-time investigatiol gene therapy candidate for adults with MPS II (Hunter Syndrome)
Oct 18, 2021: JCR Pharmaceuticals Co : EMA grants PRIME desigtion for JR-141 for the treatment of Mucopolysaccharidosis type II (Hunter Syndrome)
Oct 15, 2021: JR-141 (Pabifusp Alfa) for Hunter syndrome notice on the publication of a nonclinical and clinical evidence in Intertiol Jourl of Molecular Sciences
Jul 29, 2021: JCR Pharmaceuticals announces presentation at 16th Intertiol Symposium on MPS and Related Diseases.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Apteeus SAS, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AVROBIO Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Biorchestra Co Ltd, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Capsida Biotherapeutics Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Denali Therapeutics Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Esteve Pharmaceuticals SA, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by GC Biopharma Corp, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Generium, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Homology Medicines Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Immusoft Corp, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ReqMed Co Ltd, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sigilon Therapeutics Inc, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, 2022
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, 2022